Your browser doesn't support javascript.
loading
A multidisciplinary approach to optimize primary prostate cancer biobanking.
Cai, Peter Y; Asad, Muhammad; Augello, Michael A; Martin, Laura; Louie, Christopher; Basourakos, Spyridon P; Gaffney, Christopher D; Shoag, Jonathan; Tu, Jiangling Jenny; Khani, Francesca; Mosquera, Juan Miguel; Loda, Massimo; Scherr, Douglas S; Barbieri, Christopher E; Robinson, Brian D.
Afiliação
  • Cai PY; Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
  • Asad M; Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
  • Augello MA; Meyer Cancer Center, Weill Cornell Medicine, New York, NY.
  • Martin L; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY.
  • Louie C; Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
  • Basourakos SP; Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
  • Gaffney CD; Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
  • Shoag J; Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH.
  • Tu JJ; Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
  • Khani F; Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY.
  • Mosquera JM; Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY.
  • Loda M; Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, New York, NY.
  • Scherr DS; Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
  • Barbieri CE; Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, New York, NY. Electronic address: chb9074@med.cornell.edu.
  • Robinson BD; Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY; Meyer Cancer Center, Weill Cornell Medicine, New York, NY; Englander Institute for Preci
Urol Oncol ; 40(6): 271.e1-271.e7, 2022 06.
Article em En | MEDLINE | ID: mdl-35490048
PURPOSE: Biobanking tissue of high quality and fidelity is imperative for cancer genomics research. Since it is a challenging process, we sought to develop a protocol that improves the fidelity and quantity of biobanked primary prostate cancer (CaP) tissue. MATERIALS AND METHODS: We conducted a pilot study evaluating pathologic concordance of biobanked tissue and the radical prostatectomy specimen using either standard protocol (SP) vs. next-generation protocol (NGP). RESULTS: There were no significant differences in clinical and pathologic characteristics (age, BMI, preoperative PSA, prostate weight, race, final prostatectomy Gleason score, or pathologic tumor and nodal stages) between the two protocol arms. Utilization of the NGP compared to the standard protocol resulted in a significantly higher rate of pathologic concordance between the biobanked and RP specimens (61.8% vs. 37.9%, P = 0.0231) as well as a nearly two-fold increase in the amount of biobanked tumor tissue (330 mm3 vs. 174 mm3, P < 0.001). When looking at relevant clinical and pathologic characteristics, NGP was associated with pathologic concordance on both univariate [OR 2.65 (95% CI 1.13-6.21), P = 0.025] and multivariate analysis [OR 3.11 (95% CI 1.09-8.88), P = 0.034]. CONCLUSIONS: Our study validates the NGP as a multidisciplinary approach for improving the fidelity and amount of biobanked primary CaP tissue for future studies. Given the challenges to banking tissue from primary CaP as tumors are often difficult to visualize grossly and are frequently multifocal, optimizing the fidelity and volume of biobanked tissue is an important step forward to improve the generalizability of genomic data as we move towards precision medicine.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Guideline Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata Tipo de estudo: Guideline Limite: Humans / Male Idioma: En Ano de publicação: 2022 Tipo de documento: Article